Collateral Therapeutics' President Christopher Reinhard Talks to The Wall Street Transcript.Business Editors NEW YORK--(BUSINESS WIRE)--Sept. 19, 2001 The Wall Street Transcript has published an in-depth interview with Christopher Reinhard Christopher Reinhard (born May 19 1985 in Offenbach am Main) is a German footballer. He currently plays for Karlsruher SC. External links
Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. , Inc. (Nasdaq:CLTX), in which he talks at length about the company and its product candidates. The entire 3,200-word interview is available free online at http://www.twst.com/ceos.htm Mr. Reinhard gives an overview of the company. "Collateral Therapeutics is focused on the discovery, development, and commercialization of cardiovascular gene therapy products. Jack Reich, the CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , and I are co-Founders of the company, which was incorporated in 1995. Collateral Therapeutics occupies a very unique therapeutic space. While there are risks associated with the development of new technologies like ours, which we describe in our SEC filings, we believe we are the only company focused on developing large market opportunity cardiovascular gene therapy products." Mr. Reinhard explains the current development stage of GENERX(TM), "Our lead product, GENERX is entering large-scale Phase 2b/3 studies. The clinical program includes two pivotal studies; one study in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. at up to 100 medical centers and another study in Europe. In the U.S., we'll be evaluating patients with stable exertional angina Angina Definition Angina is pain, "discomfort," or pressure localized in the chest that is caused by an insufficient supply of blood (ischemia) to the heart muscle. due to coronary artery disease coronary artery disease, condition that results when the coronary arteries are narrowed or occluded, most commonly by atherosclerotic deposits of fibrous and fatty tissue. . According to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. the American Heart Association American Heart Association (AHA), n.pr a national voluntary health agency that has the goal of increasing public and medical awareness of cardiovascular diseases and stroke, and thereby reducing the number of associated deaths and disabilities. , there are approximately 12 million people in the U.S. who have coronary artery disease and about half of them or 6 million people have coronary artery disease advanced to a point where they seek medical treatment for chest pain. That pain is called "angina." We seek to develop GENERX as a new alternative for the treatment of patients with stable exertional angina." Looking forward, Mr. Reinhard states, "As our clinical trials advance and we move forward on further developing our pipeline and potential partnering activities in the next year, I think the public will begin to better understand the success that we have had and more fully realize the significant investment opportunity that Collateral Therapeutics now offers." This interview is part of a 352-page Bear, Stearns & Company 14th Annual Healthcare Conference Issue available at http://www.twst.com/info/info418.htm or by calling 212/952-7433. The Wall Street Transcript does not endorse the views of any interviewees nor does it make stock recommendations. For subscription information call 800/246-7673. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion